ONCOCROSS

  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News/IR

    • Announcement

    • Press

    • Regulatory Disclosure

    • Stock Information

CONTACT US
한
  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News/IR

    • Announcement

    • Press

    • Regulatory Disclosure

    • Stock Information

  • 한
  • EN
CONTACT US
  • Main
  • News/IR
  • Press

머니투데이

'AI신약' 온코크로스, 동화약품과 항암제 적응증 공동연구계약

  • 01-17-2022
https://news.mt.co.kr/mtview.php?no=2022011710045119890&type=1
Previous
모더나 공동 설립자 “디지털 생물학 시대 도래”…AI 신약 기술 기업에 쏠리는 눈 01-17-2022
Next
모더나 공동 설립자 “디지털 생물학 시대 도래”…AI 신약 기술 기업에 쏠리는 눈 01-17-2022
List

Please enter a prompt

ONCOCROSS
CEO
Yi Rang KIM / Jihoon KANG
Address
#905 7 Beobwon-ro 11-gil, Songpa-gu, Seoul, 05836, Korea
Tel
02-717-9967
Fax
02-867-9968
Email
oncocross@oncocross.com
Terms & Conditions Privacy Policy Cookie Policy
ⓒ ONCOCROSS CO., LTD. All Rights Reserved.